-
Keji Pharmaceutical's independent research and development of CAR-T product CT041 was approved for Canadian clinical trial
Time of Update: 2022-01-04
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
HK), an innovative CAR-T cell therapy company focused on the treatment of hematological malignancies and solid tumors, announced today, The company's self-developed CT041, an autologous CAR-T candidate for CLDN 18.
-
Global COVID-19 security innovation company expands products
Time of Update: 2022-01-04
S. Occupational Safety and Health Administration Coronavirus Disease RulesBoston, November 24, 2021/PRNewswire/ - Safely2Prosperity LLC CEO, JD, MBA John Norris announced the launch of a new S2P "COVID-19 Security Platform" and "Employee Dashboard" to achieve Quick demonstration and immediate deployment .
-
One machine with multiple functions, the industry leader – Fluidigm Biomark™ X is now on the market!
Time of Update: 2022-01-04
"Today, with Biomark X, we have taken the powerful microfluidic platform to a new level, minimizing manual operation time, allowing researchers to focus on more important issues .
-
Sign up now!
Time of Update: 2022-01-04
After two years, the highly anticipated PR News News Annual Forum is back again! This year, with the theme of "Restart·New Knowledge", we will continue to discuss ideas with hundreds of communication
-
Cinda Bio announced that its stock (01801.HK) was included in the Hang Seng China Enterprise Index
Time of Update: 2022-01-04
62em; font-family:"Arial"; color:black; margin:0in; } </>San Francisco, USA and Suzhou, China November 22, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the treatment of tumors, metabolic diseases, A biopharmaceutical company that has innovative drugs for major diseases such as autoimmune has announced that according to the latest adjustment results announced by the Hang Seng Index Company , the company’s stock (01801.
-
Tianyan Pharmaceuticals announced that it will publish the clinical data of two new epitope original antibody projects in the form of posters at the ESMO conference in 2021
Time of Update: 2022-01-04
<> /* Style Definitions */ span. prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a. prnews_a { color:blue; } li. prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p. prn
-
Kaifeng Pharmaceutical Freedane for the treatment of male androgenetic alopecia registered Phase III clinical trial approved by NMPA
Time of Update: 2022-01-04
. The company announced on September 8 this year that the China Phase II clinical trial of freitan for the treatment of male androgenetic alopecia patients has reached the clinical endpoint.
-
Nuocheng Jianhua enters the list of the most valuable TOP20 biomedical companies in Asia
Time of Update: 2022-01-04
prntblns{ BORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt } Beijing, November 22, 2021/PRNewswire/ - According to the latest "The Pharma 1000 List" released by the global investment bank Torreya, the biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange) Code: 09969) entered the list of 20 Most Valuable Biotechs in Asia (20 Most Valuable Biotechs in Asia) and ranked ninth .
-
Hepatitis drugs increase the effectiveness of antibiotics and limit antibiotic resistance
Time of Update: 2022-01-04
A new study published in the journal Cell Chemical Biology by New York University researchers shows that FDA-approved hepatitis C drugs can increase the sensitivity of bacteria to antibiotics and reduce the possibility of antibiotic resistance .
-
Twins study found that type 2 diabetes is linked to epigenetic changes
Time of Update: 2022-01-04
The researchers analyzed DNA methylation and microRNA in fat slices from a pair of twins to further understand why only one of the twins had type 2 diabetes .
-
WuXi Biologics Plant 5 completed the first batch of GMP and successfully produced 24,000 liters of stock solution production line
Time of Update: 2022-01-04
prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.
prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.
24,000 liters of stock solution production line at WuXi Biologics Plant No.
For more information, please contactMedia Relations PR@wuxibiologics.
-
China's first bone and soft tissue tumor NGS expert consensus to help clinical precision diagnosis and treatment
Time of Update: 2022-01-03
Professor Niu Xiaohui, a member of the consensus expert group and the Department of Orthopedic Oncology, Beijing Jishuitan Hospital, said, “NGS testing provides a new and powerful tool for the clinical diagnosis and treatment of bone and soft tissue tumors .
-
COVID-19 test kit can also detect oral microbiota in saliva
Time of Update: 2022-01-03
Abigail Armstrong, a postdoctoral fellow at the Center for Advanced Biotechnology and Medicine (CABM) at Rutgers University and lead author of the study, said: "We inhale a small amount of saliva every day, so it makes sense that some of the microorganisms in our mouths end up in our lungs .
-
Inspur Information and Chengdu University of Traditional Chinese Medicine Affiliated Hospital jointly explore the digitalization of TCM diagnosis and treatment
Time of Update: 2022-01-03
In the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Inspur Information and the hospital are jointly exploring the upgrade path of the "Compendium of Materia Medica" in the digital age.
-
Molnupiravir follow-up report: The effective rate of oral new coronavirus is only 30%?
Time of Update: 2022-01-03
On October 1, 2021, Merck and Ridgeback announced the Phase III clinical interim data of Molnupiravir in the treatment of patients with mild to moderate COVID-19 pneumonia .
-
IDTC enters Guangzhou: From "one size fits all" to "precision medicine", Inspur storage helps the industry's digital transformation
Time of Update: 2022-01-03
Zhongshan Sixth Hospital has built a digital life resource database based on the Inspur distributed storage platform, and is promoting the application of big data and artificial intelligence technology in the field of precision medicine to help cancer patients obtain personalized treatment plans .
-
Fuhong Henlius' innovative anti-PD-L1/TIGIT dual antibody was approved to carry out clinical trials in Australia
Time of Update: 2022-01-03
HK) announced that the company's self-developed recombinant human anti-PD-L1 and anti-TIGIT bispecific antibody injection HLX301 has passed Australian drugs The Therapeutic Goods Administration (TGA) clinical trial filing was approved to carry out a phase 1 clinical study in Australia, which is intended to be used for the treatment of locally advanced or metastatic solid tumors .
-
Focus on spinal cord injury Coloplast helps promote international academic exchanges and cooperation
Time of Update: 2022-01-03
62em; font-family:"Arial"; color:black; margin:0in; } </>Beijing, November 25, 2021/PRNewswire/ - Recently, the China Rehabilitation Research Center and the Neuroscience Center of the National Hospital of Denmark, the Department of Neuroscience and Spinal Cord Injury, reached a cooperation agreement and formally signed a contract in various academic fields related to spinal cord injury .
-
Ipsen Multi-Health joins hands with China Green Club to help rural children drink clean water
Time of Update: 2022-01-03
62em; font-family:"Arial"; color:black; margin:0in; } </>Beijing , November 25, 2021/PRNewswire/ - Recently, Ipsen Multi-Health and the China Biodiversity Conservation and Green Development Foundation Water Security Public Welfare Fund ("Water Security Fund") cooperated to provide Bijie City, Guizhou Province Children from three subordinate schools of Xinfang Yi and Miao Township Hope Primary School, Xinfang Township Huangjiatun Primary School in Nayong County, and Xinfang Yi and Miao Township Yingpan Primary School donated water purifier equipment .
-
Approximately 12% of patients receiving ordinary heart device implants will continue to use opioids
Time of Update: 2022-01-03
They will continue to use painkillers for several months after surgery, according to the University of Pennsylvania A new study by researchers at the Perelman School of Medicine uses these common procedures to increase the likelihood of addiction and identify another route that could lead to a national opioid crisis .
